221 related articles for article (PubMed ID: 31387520)
21. 1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6.
Nominé Y; Charbonnier S; Miguet L; Potier N; Van Dorsselaer A; Atkinson RA; Travé G; Kieffer B
J Biomol NMR; 2005 Feb; 31(2):129-41. PubMed ID: 15772752
[TBL] [Abstract][Full Text] [Related]
22. Molecular Landscape and Computational Screening of the Natural inhibitors against HPV16 E6 Oncoprotein.
Juneja T; Pandya MD; Shah S
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2461-2469. PubMed ID: 34452559
[TBL] [Abstract][Full Text] [Related]
23. A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.
Dymalla S; Scheffner M; Weber E; Sehr P; Lohrey C; Hoppe-Seyler F; Hoppe-Seyler K
J Mol Med (Berl); 2009 Mar; 87(3):321-31. PubMed ID: 19099279
[TBL] [Abstract][Full Text] [Related]
24. Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins.
Harden ME; Prasad N; Griffiths A; Munger K
mBio; 2017 Jan; 8(1):. PubMed ID: 28049151
[TBL] [Abstract][Full Text] [Related]
25. Production of functional, stable, unmutated recombinant human papillomavirus E6 oncoprotein: implications for HPV-tumor diagnosis and therapy.
Illiano E; Demurtas OC; Massa S; Di Bonito P; Consalvi V; Chiaraluce R; Zanotto C; De Giuli Morghen C; Radaelli A; Venuti A; Franconi R
J Transl Med; 2016 Jul; 14(1):224. PubMed ID: 27465494
[TBL] [Abstract][Full Text] [Related]
26. HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
Wang Q; Song R; Zhao C; Liu H; Yang Y; Gu S; Feng D; He J
Int J Cancer; 2019 Apr; 144(7):1619-1632. PubMed ID: 30230542
[TBL] [Abstract][Full Text] [Related]
27. Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus.
Karlsson OA; Ramirez J; Öberg D; Malmqvist T; Engström Å; Friberg M; Chi CN; Widersten M; Travé G; Nilsson MT; Jemth P
Sci Rep; 2015 Mar; 5():9382. PubMed ID: 25797137
[TBL] [Abstract][Full Text] [Related]
28. Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells.
He H; Liu X; Liu Y; Zhang M; Lai Y; Hao Y; Wang Q; Shi D; Wang N; Luo XG; Ma W; Zhang TC
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728257
[TBL] [Abstract][Full Text] [Related]
29. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.
Baleja JD; Cherry JJ; Liu Z; Gao H; Nicklaus MC; Voigt JH; Chen JJ; Androphy EJ
Antiviral Res; 2006 Oct; 72(1):49-59. PubMed ID: 16690141
[TBL] [Abstract][Full Text] [Related]
30. E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78.
Ajiro M; Zheng ZM
mBio; 2015 Feb; 6(1):e02068-14. PubMed ID: 25691589
[TBL] [Abstract][Full Text] [Related]
31. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
32. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
33. Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations.
Meza-Menchaca T; Lizano-Soberón M; Trigos A; Zepeda RC; Medina ME; Galindo-Murillo R
Med Chem; 2021; 17(6):587-600. PubMed ID: 31995016
[TBL] [Abstract][Full Text] [Related]
34. HPV16 E6 Controls the Gap Junction Protein Cx43 in Cervical Tumour Cells.
Sun P; Dong L; MacDonald AI; Akbari S; Edward M; Hodgins MB; Johnstone SR; Graham SV
Viruses; 2015 Oct; 7(10):5243-56. PubMed ID: 26445057
[TBL] [Abstract][Full Text] [Related]
35. E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the
Chen X; Loo JX; Shi X; Xiong W; Guo Y; Ke H; Yang M; Jiang Y; Xia S; Zhao M; Zhong S; He C; Fu L; Li F
Cancer Res; 2018 Mar; 78(6):1418-1430. PubMed ID: 29339538
[TBL] [Abstract][Full Text] [Related]
36. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
Bourguignon LYW; Earle C; Shiina M
Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
[TBL] [Abstract][Full Text] [Related]
37. Human papilloma virus 16 E6 protein as a target for curcuminoids, curcumin conjugates and congeners for chemoprevention of oral and cervical cancers.
Singh AK; Misra K
Interdiscip Sci; 2013 Jun; 5(2):112-8. PubMed ID: 23740392
[TBL] [Abstract][Full Text] [Related]
38. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
39. Elevated Expression of Human Papillomavirus-16/18 E6 Oncoprotein Associates with Persistence of Viral Infection: A 3-Year Prospective Study in China.
Yu LL; Kang LN; Zhao FH; Lei XQ; Qin Y; Wu ZN; Wang H; Chen W; Qiao YL
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1167-74. PubMed ID: 27197295
[TBL] [Abstract][Full Text] [Related]
40. In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response.
Shah M; Anwar MA; Park S; Jafri SS; Choi S
Sci Rep; 2015 Aug; 5():13446. PubMed ID: 26289783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
